Physician profile
Alan Chang
NPI 1649408675
$3,305.39
in general payments reported to CMS, 2019-2025
22 companies · $1,219 in 2025
The $1,219 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $125 · 2021: $171 · 2022: $271 · 2023: $694 · 2024: $671 · 2025: $1,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,559 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,559.10 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $466.77 | 2022-2024 | Wegovy |
| Beta Bionics, INC. | $399.05 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Insulet Corporation | $350.38 | 2024-2025 | Omnipod, Omnipod |
| Abbott Laboratories | $345.95 | 2024 | Freestyle Libre 3 |
| Amgen INC. | $236.15 | 2022-2023 | Evenity |
| Medtronic, INC. | $225.73 | 2025 | Minimed 780g |
| Dexcom, INC. | $172.08 | 2025 | Dexcom G6 Transmitter |
| Mannkind Corporation | $155.48 | 2021 | |
| Xeris Pharmaceuticals, INC. | $146.32 | 2023-2024 | Gvoke Hypopen |
| Lilly USA, LLC | $130.54 | 2019-2023 | Jardiance |
| Alexion Pharmaceuticals, INC. | $126.75 | 2025 | Strensiq |
| Sanofi-Aventis U.S. LLC | $124.96 | 2020 | |
| Merck Sharp & Dohme LLC | $111.24 | 2019 | |
| Pfizer INC. | $69.99 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $55.42 | 2023 | Rebyota |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $49.54 | 2024 | Tymlos |
| Tandem Diabetes Care, INC. | $30.94 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascendis Pharma Endocrinology INC | $26.76 | 2025 | Yorvipath |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Recordati_rare_diseases_inc. | $22.53 | 2025 | Isturisa |
| Cequr Corporation | $20.00 | 2025 | Cequr Simplicity |
| Takeda Pharmaceuticals U.S.A., INC. | $13.81 | 2023 | Gattex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.